MedTrace Logo

Efficacy of Aligners vs ABT and RCOS for Deep Bite Correction: CBCT Study

NCT07096401 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-08-03

No results posted yet for this study

Summary

This prospective clinical trial aims to evaluate the efficacy of clear aligner therapy compared to two different treatment modalities - anterior bite turbos and reverse curve of Spee (RCOS) archwires - for the correction of dental deep bite cases. Deep bite malocclusion is characterized by excessive vertical overlap of the anterior teeth and often requires intrusion of anterior teeth and leveling of the curve of Spee.

In this study, 27 patients aged 16-30 years with an overbite ≥5 mm and no significant skeletal discrepancies will be randomly assigned into three equal groups: Group 1 (RCOS archwire), Group 2 (anterior bite turbos), and Group 3 (clear aligners).

Cone-beam computed tomography (CBCT) will be used to assess changes in overbite and alveolar bone height and thickness before and after treatment. The primary outcome is the efficacy of overbite correction, and the secondary outcome is the assessment of alveolar bone remodeling.

The study will be conducted at the Department of Orthodontics, Faculty of Dental Medicine, Al-Azhar University (Assiut Branch), and has been approved by the institutional ethical committee.

Conditions

  • Deep Bite Malocclusion

Interventions

DEVICE

Reverse Curve of Spee Archwire

Orthodontic treatment using a 0.016 × 0.022 NiTi reverse curve of Spee archwire to correct deep bite through posterior extrusion and anterior intrusion.

DEVICE

Anterior Bite Turbos

Orthodontic treatment using anterior bite turbos bonded to the palatal surfaces of the upper central incisors to promote posterior extrusion and correct deep bite.

DEVICE

Clear Aligners

Orthodontic treatment using clear aligner therapy designed for anterior intrusion and leveling of the curve of Spee to correct deep bite.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2026-10-01
Completion
2027-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07096401 on ClinicalTrials.gov